Biogen Inc. (BIIB) Q3 2011 Earnings Results

Biogen Beats on EPS, Stock Up 0.83%

Biogen's earnings report showed a positive surprise in EPS, which contributed to a slight increase in stock price. The lack of revenue data and guidance may leave some investors cautious. Overall, the company is maintaining a focus on innovation, which could be a positive sign for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.61	N/A	+6.48%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

We are pleased with our EPS performance this quarter.

Our focus remains on delivering value through our innovative therapies.

Biogen Beats on EPS, Stock Up 0.83%

Key numbers

Management commentary

Biogen Inc.

More earnings this week

Biogen Beats on EPS, Stock Up 0.83%

Key numbers

Management commentary